Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313431328> ?p ?o ?g. }
Showing items 1 to 91 of
91
with 100 items per page.
- W4313431328 abstract "Background: Dupilumab, a human monoclonal antibody, blocks the shared receptor component for interleukins 4/13, key and central drivers of type 2 inflammation. The LIBERTY ASTHMA TRAVERSE (NCT02134028) open-label extension study demonstrated the long-term safety and efficacy of dupilumab in patients ≥12 years who had participated in a previous dupilumab asthma study. The safety profile was consistent with that observed in the parent studies. Methods: This analysis includes patients from phase 2b (NCT01854047) or phase 3 (QUEST; NCT02414854) studies receiving high- or medium-dose inhaled corticosteroids (ICS) at parent study baseline (PSBL) and enrolled in TRAVERSE. We analyzed unadjusted annualized severe exacerbation rates, change from PSBL in pre-bronchodilator (pre-BD) FEV (L), asthma control (5-item asthma control questionnaire), and type 2 biomarkers in patients with type 2 asthma at baseline (blood eosinophils ≥150 cells/µL or fractional exhaled nitric oxide [FeNO] ≥25 ppb), and subgroups defined by baseline blood eosinophils or FeNO. Results: Of patients with type 2 asthma (n=1,666) in this analysis, 891 (53.5%) were receiving high‑dose ICS at PSBL. In this subgroup, unadjusted exacerbation rates for dupilumab vs placebo were 0.517 vs. 1.883 (phase 2b) and 0.571 vs. 1.300 (QUEST) over 52 weeks of the parent study, and remained low throughout TRAVERSE (0.313–0.494). Improvements in pre-BD FEV from PSBL were sustained throughout TRAVERSE. Similar clinical efficacy was observed among patients receiving medium-dose ICS at PSBL and biomarker subgroups. Conclusions: Dupilumab showed sustained efficacy for up to 3 years in patients with uncontrolled, moderate-to-severe type 2 asthma on high- or medium-dose ICS." @default.
- W4313431328 created "2023-01-06" @default.
- W4313431328 creator A5002590978 @default.
- W4313431328 creator A5011255987 @default.
- W4313431328 creator A5016161340 @default.
- W4313431328 creator A5017155583 @default.
- W4313431328 creator A5017711682 @default.
- W4313431328 creator A5021417774 @default.
- W4313431328 creator A5024974445 @default.
- W4313431328 creator A5032063153 @default.
- W4313431328 creator A5037227971 @default.
- W4313431328 creator A5038824744 @default.
- W4313431328 creator A5043657394 @default.
- W4313431328 creator A5045980264 @default.
- W4313431328 creator A5059328493 @default.
- W4313431328 creator A5069220861 @default.
- W4313431328 date "2022-12-20" @default.
- W4313431328 modified "2023-10-16" @default.
- W4313431328 title "Dupilumab sustains efficacy in patients with moderate-to-severe type 2 asthma regardless of ICS dose" @default.
- W4313431328 doi "https://doi.org/10.22541/au.167151101.13413168/v1" @default.
- W4313431328 hasPublicationYear "2022" @default.
- W4313431328 type Work @default.
- W4313431328 citedByCount "0" @default.
- W4313431328 crossrefType "posted-content" @default.
- W4313431328 hasAuthorship W4313431328A5002590978 @default.
- W4313431328 hasAuthorship W4313431328A5011255987 @default.
- W4313431328 hasAuthorship W4313431328A5016161340 @default.
- W4313431328 hasAuthorship W4313431328A5017155583 @default.
- W4313431328 hasAuthorship W4313431328A5017711682 @default.
- W4313431328 hasAuthorship W4313431328A5021417774 @default.
- W4313431328 hasAuthorship W4313431328A5024974445 @default.
- W4313431328 hasAuthorship W4313431328A5032063153 @default.
- W4313431328 hasAuthorship W4313431328A5037227971 @default.
- W4313431328 hasAuthorship W4313431328A5038824744 @default.
- W4313431328 hasAuthorship W4313431328A5043657394 @default.
- W4313431328 hasAuthorship W4313431328A5045980264 @default.
- W4313431328 hasAuthorship W4313431328A5059328493 @default.
- W4313431328 hasAuthorship W4313431328A5069220861 @default.
- W4313431328 hasBestOaLocation W43134313281 @default.
- W4313431328 hasConcept C126322002 @default.
- W4313431328 hasConcept C142724271 @default.
- W4313431328 hasConcept C185592680 @default.
- W4313431328 hasConcept C203014093 @default.
- W4313431328 hasConcept C204787440 @default.
- W4313431328 hasConcept C27081682 @default.
- W4313431328 hasConcept C2776042228 @default.
- W4313431328 hasConcept C2777014857 @default.
- W4313431328 hasConcept C2777037409 @default.
- W4313431328 hasConcept C2777832160 @default.
- W4313431328 hasConcept C2779185760 @default.
- W4313431328 hasConcept C2779824493 @default.
- W4313431328 hasConcept C2780333948 @default.
- W4313431328 hasConcept C2781142857 @default.
- W4313431328 hasConcept C2781197716 @default.
- W4313431328 hasConcept C55493867 @default.
- W4313431328 hasConcept C71924100 @default.
- W4313431328 hasConcept C90924648 @default.
- W4313431328 hasConceptScore W4313431328C126322002 @default.
- W4313431328 hasConceptScore W4313431328C142724271 @default.
- W4313431328 hasConceptScore W4313431328C185592680 @default.
- W4313431328 hasConceptScore W4313431328C203014093 @default.
- W4313431328 hasConceptScore W4313431328C204787440 @default.
- W4313431328 hasConceptScore W4313431328C27081682 @default.
- W4313431328 hasConceptScore W4313431328C2776042228 @default.
- W4313431328 hasConceptScore W4313431328C2777014857 @default.
- W4313431328 hasConceptScore W4313431328C2777037409 @default.
- W4313431328 hasConceptScore W4313431328C2777832160 @default.
- W4313431328 hasConceptScore W4313431328C2779185760 @default.
- W4313431328 hasConceptScore W4313431328C2779824493 @default.
- W4313431328 hasConceptScore W4313431328C2780333948 @default.
- W4313431328 hasConceptScore W4313431328C2781142857 @default.
- W4313431328 hasConceptScore W4313431328C2781197716 @default.
- W4313431328 hasConceptScore W4313431328C55493867 @default.
- W4313431328 hasConceptScore W4313431328C71924100 @default.
- W4313431328 hasConceptScore W4313431328C90924648 @default.
- W4313431328 hasLocation W43134313281 @default.
- W4313431328 hasOpenAccess W4313431328 @default.
- W4313431328 hasPrimaryLocation W43134313281 @default.
- W4313431328 hasRelatedWork W2120222132 @default.
- W4313431328 hasRelatedWork W2901676388 @default.
- W4313431328 hasRelatedWork W2922038653 @default.
- W4313431328 hasRelatedWork W2982906595 @default.
- W4313431328 hasRelatedWork W3097826995 @default.
- W4313431328 hasRelatedWork W3135286774 @default.
- W4313431328 hasRelatedWork W4214654850 @default.
- W4313431328 hasRelatedWork W4292737569 @default.
- W4313431328 hasRelatedWork W4312280085 @default.
- W4313431328 hasRelatedWork W4313431328 @default.
- W4313431328 isParatext "false" @default.
- W4313431328 isRetracted "false" @default.
- W4313431328 workType "article" @default.